Susan M. Langan-Fahey

Author

University of Wisconsin–Madison

Also Known As

S M Langan-Fahey, S. Langan-Fahey, S. M. Langan-Fahey, Susan M. Langan-Fahey

Publications

Citations

H-Index

Concepts

All Affiliations

University of Wisconsin–Madison University of Wisconsin Carbone Cancer Center Breast Cancer Care

About

Susan M. Langan-Fahey is an author at University of Wisconsin–Madison specializing in breast cancer, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	453
2	Cell Biology	4	4	182
3	Endocrinology	2	2	210
4	Health Sciences	1	1	58
5	Immunology	1	1	11

Susan M. Langan-Fahey

Publications

Citations

H-Index

Page 1

	Year	Citations
Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. S P Robinson, Susan M. Langan-Fahey, D A Johnson, Drug Metabolism and Disposition	1991	272
Alteration of Endocrine Parameters in Premenopausal Women With Breast Cancer During Long-Term Adjuvant Therapy With Tamoxifen as the Single Agent V. Craig Jordan, Nancy F. Fritz, Susan M. Langan-Fahey, JNCI Journal of the National Cancer Institute Breast OncologyGynecologyMenopausal Hormone TherapyEndocrine ParametersFemale Reproductive Function	1991	152
Suppression of Mouse Mammary Tumorigenesis by Long-Term Tamoxifen Therapy V. Craig Jordan, Mary K. Lababidi, Susan M. Langan-Fahey JNCI Journal of the National Cancer Institute	1991	136
Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer Susan M. Langan-Fahey, Douglass C. Tormey, V. Craig Jordan European Journal of Cancer and Clinical Oncology Breast OncologyOncologyMedicineBreast CancerPharmacotherapy	1990	119
Investigation of the Mechanism of Tamoxifen-Stimulated Breast Tumor Growth With Nonisomerizable Analogues of Tamoxifen and Metabolites Danny Wolf, Susan M. Langan-Fahey, Christopher Parker, JNCI Journal of the National Cancer Institute	1993	93
Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Catherine S. Murphy, Susan M. Langan-Fahey, R. MCCAGUE, Molecular Pharmacology	1990	83
Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Shaoyun Jiang, Susan M. Langan-Fahey, A L Stella, Molecular Endocrinology Radiation OncologyBreast OncologyAntiestrogen TamoxifenMedicineHormonal Receptor	1992	75
Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells. Meei Huey Jeng, Susan M. Langan-Fahey, V. Craig Jordan Endocrinology Breast OncologyChemoprevention StrategyEstrogen ReceptorCell ProliferationCancer Biology	1993	58
Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts Simon P. Robinson, Susan M. Langan-Fahey, V. Craig Jordan European Journal of Cancer and Clinical Oncology Tamoxifen MetabolismBreast OncologyOncologyMedicineAthymic Mouse	1989	38
Human recombinant interferon-?SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse David F. Gibson, Delinda A. Johnson, David Goldstein, Breast Cancer Research and Treatment Breast OncologyImmunologyCancer GrowthAthymic MouseBreast Cancer	1993	11

Page 1